

PGA5

Native Human Pepsinogen I

| | | | |
|---------------------------------|---|------------------|--------------------------|
| Catalog No. | CNH002A CNH002B CNH002C | Quantity: | 100 µg 500 µg 1 mg |
| Alternate Names: | Pepsinogen A, PG1, PGA | | |
| Description: | Human Pepsinogens are aspartic proteases produced in the gastric mucosa and secreted into the gastric lumen that play a major role in the digestion of proteins after activation at acidic pH. Pepsinogen is synthesized as isoenzymes and are classified into two groups, I and II. | | |
| Appearance: | White lyophilizate | | |
| Gene ID: | 5222 | | |
| Source: | Human Gastric Mucosa | | |
| Molecular Weight: | 45.0 kDa | | |
| Formulation: | Lyophilized from Tris HCl, pH 8.5 | | |
| Purity: | >90% by SDS-PAGE (may contain minor cleavage products). Identity confirmed by Western blot. | | |
| Specific Activity: | > 500 U/mg protein (after activation). One unit will produce a ΔA_{280} of 0.001 per minute at pH 2.0 and 37°C, measured as TCA-soluble products from hemoglobin. | | |
| Reconstitution: | After reconstitution, maintain at or above pH 8.0 to avoid activation. | | |
| Solubility: | Produces a clear, colorless solution at 1 mg/ml in saline. | | |
| Storage & Stability: | Store at -20°C. 2 years from manufacture. Avoid repeated freeze-thaw cycles. | | |
| Certification: | Non-Infectious Disease Certification: Non-reactive for HIV-1/HCV/HBV by NAT; HBsAg, HCV Ab, HIV-1&2 Ab and RPR by currently approved FDA methods. However, because no test method can offer complete assurance that infectious agents are absent, this material should be handled at Bio-Safety Level 2 (BSL 2) as recommended for potentially infectious human serum or blood specimen in the CCD/NIH manual "Biosafety in Microbiological and Biomedical Laboratories", 1999. | | |

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

